<DOC>
	<DOC>NCT00175864</DOC>
	<brief_summary>This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.</brief_summary>
	<brief_title>Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>An IRB/IEC approved written informed consent form signed and dated Male/Female patients age 18 (or 16 years where permitted by law) to 65. Minimum body weight of 40 kg. Patients with a confirmed diagnosis of refractory epilepsy of ≥ 6 months. Patients must be receiving 1 3 concomitant AEDs. Female patients without childbearing potentials (2 years postmenopausal or surgical sterilization) are eligible. Female patients with childbearing potential are eligible if they use a medically accepted nonhormonal contraceptive method. Seizures occurring in clusters (seizures occurring either too frequently or indistinctly separated to be reliably counted). Status epilepticus within 3 months of Visit 1. History of nonepileptic seizures. Patients on vigabatrin. Patients on felbamate, unless treatment has been continuous for ≥ 18 months. Use of benzodiazepines (for any indication) taken at a higher frequency than an average of once a week, unless counted as one of the concomitant AEDs. Ongoing psychiatric disease other than mild controlled disorders. Patients with a clinically significant organ dysfunction. Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients. Pregnant or lactating women. Any woman with childbearing potential who is not using a medically accepted, nonhormonal method of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Partial Onset, Primary Generalized Seizures, Seletracetam</keyword>
</DOC>